1
Clinical Trials associated with Tetravalent blending VDV-2/CYD-1,3,4 Dengue Vaccine(Sanofi Pasteur)Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years
This is part of an ongoing effort to develop a satisfactory dengue vaccine:
Primary objective:
To describe the safety after each vaccination with bivalent and tetravalent formulations of dengue vaccine candidates.
To describe the immune response after each vaccination of dengue vaccine.
100 Clinical Results associated with Tetravalent blending VDV-2/CYD-1,3,4 Dengue Vaccine(Sanofi Pasteur)
100 Translational Medicine associated with Tetravalent blending VDV-2/CYD-1,3,4 Dengue Vaccine(Sanofi Pasteur)
100 Patents (Medical) associated with Tetravalent blending VDV-2/CYD-1,3,4 Dengue Vaccine(Sanofi Pasteur)
100 Deals associated with Tetravalent blending VDV-2/CYD-1,3,4 Dengue Vaccine(Sanofi Pasteur)